GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 313
- Registration Number
- NCT01498653
- Locations
- 🇵🇭
GSK Investigational Site, Quezon City, Philippines
Cervarix Long-term Safety Surveillance
Completed
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: CervarixOther: Data collection
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2015-04-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2945
- Registration Number
- NCT01498627
A Multiple Use Tolerability Study of a Breathe Right Nasal Strip Prototype
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Device: Prototype Nasal DilatorDevice: Marketed Nasal Strip
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT01495494
- Locations
- 🇺🇸
Essex Testing Clinic, Inc, Verona, New Jersey, United States
The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects
Phase 1
Completed
- Conditions
- Cough
- Interventions
- Drug: GSK2339345 (nebulised)Drug: GSK2339345 (solution)Drug: Placebo (0.9% sodium chloride solution)
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 31
- Registration Number
- NCT01494636
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers
Phase 1
Terminated
- Conditions
- Community-acquired Infection
- Interventions
- Drug: GSK2251052 2250 mgDrug: GSK2251052 750 mgDrug: GSK2251052 1500 mgDrug: GSK2251052 3000 mgDrug: GSK2251052 0.9% salineDrug: GSK2251052 1500 mg BID
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2017-06-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT01495065
- Locations
- 🇺🇸
GSK Investigational Site, Glendale, California, United States
Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity
Not Applicable
Completed
- Conditions
- Dentinal SensitivityHypersensitivity
- Interventions
- Drug: Test ToothpasteDrug: Negative Control Toothpaste
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 118
- Registration Number
- NCT01494649
- Locations
- 🇺🇸
BioSci Research America, Inc., Las Vegas, Nevada, United States
A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2014-02-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 250
- Registration Number
- NCT01495000
- Locations
- 🇮🇳
GSK Investigational Site, Vadodra, India
A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease
Phase 4
Completed
- Conditions
- Parkinson Disease
- Interventions
- Drug: placebo/L-dopaDrug: ropinirole/L-dopa
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 352
- Registration Number
- NCT01494532
- Locations
- 🇸🇰
GSK Investigational Site, Trnava, Slovakia
A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia
Phase 1
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state)Drug: Harnal-D Tablets with water (fasted state)Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)Drug: Harnal-D Tablets with water (fed state)Drug: Harnal-D tablets without water (fasted state)
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 63
- Registration Number
- NCT01495026
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia
Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: SERETIDE RotacapsDrug: SERETIDE Diskus
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT01494610
- Locations
- 🇳🇿
GSK Investigational Site, Wellington, New Zealand
© Copyright 2025. All Rights Reserved by MedPath